Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12734366 | 0.94 | ALDH1A1 (0.31) | ALDH1A1TP53CYP1A2CYP3A4MAPT | |
| SCHEMBL1677578 | 0.93 | GCK (0.37) | GCKALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL1677382 | 0.91 | GCK (0.34) | GCKMAPT | |
| SCHEMBL12734326 | 0.90 | EGFR (0.32) | ALDH1A1TP53CYP1A2CYP3A4MAPT | |
| SCHEMBL564516 | 0.90 | GCK (0.34) | GCKAOC3 | |
| SCHEMBL13665691 | 0.90 | GCK (0.33) | GCKALDH1A1 | |
| SCHEMBL12806853 | 0.90 | GCK (0.33) | GCKALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL1677518 | 0.89 | GCK (0.33) | GCKALDH1A1MAPT | |
| SCHEMBL12807199 | 0.88 | ALDH1A1 (0.32) | GCKALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL1677907 | 0.88 | GCK (0.35) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673942-B2 | Fused ring compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8673942-B2 | Fused ring compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20110098297-A1 | FUSED RING COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-28 | — | — | US | disclosed |
| WO-2009125873-A1 | FUSED RING COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098297-A1 | FUSED RING COMPOUNDS AND USE THEREOF | GCKR, GPR119, SLC5A1 | GCK 4/4885ALDH1A1 305/4885TP53 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.